Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coherus Aiming For More Than 10% Slice Of US Adalimumab Market

US-Based Firm Has December 2021 FDA Goal Date

Executive Summary

Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.

You may also be interested in...



Coherus Moves Ahead With Pegfilgrastim On-Body Injector Rival

Coherus BioSciences is eyeing a potential late 2022/early 2023 timeline to introduce its proposed proprietary on-body injector device for its Udenyca pegfilgrastim biosimilar, after reporting positive results from a comparative clinical trial.

Biosimilars Players Climb Global Rankings

Biosimilars players are gaining an increasing foothold in the off-patent industry, as demonstrated by the final part of our annual Top 50 ranking.

Coherus Partners Formycon/Bioeq File Ranibizumab With FDA

Launch planning is underway for the Lucentis biosimilar that Coherus BioScienes has in-licensed in the US from Formycon and Bioeq, the US-based firm has revealed, as the eye-disease biologic was submitted to the US Food and Drug Administration.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150700

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel